跳至主要内容
临床试验/JPRN-jRCTs051180147
JPRN-jRCTs051180147已完成未知

FLT-PET/MRI imaging for the evaluation of early response to immune checkpoint inhibitors - FLT-PET/MRI imaging for the immune checkpoint inhibitors

meda Yukihiro0 个研究点目标入组 26 人开始时间: 2019年3月20日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
26

研究概览

简要总结

This prospective study showed that changes in TLP measured by 18F-FLT PET as early as 2 weeks after treatment initiation could have utility as predictors of the response and progression-free survival of NSCLC patients treated with anti-PD-1 antibody therapy.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • 1) Age 20 or over.
  • 2) Patients with pathologically confirmed advanced non-small cell lung cancer (NSCLC), and indication of PD-1 immune checkpoint inhibitors (nivolumab or pembrolizumab).
  • 3) Written informed consent.

排除标准

  • 1) Patients with metallic device in their body.
  • 2) Patients with claustrophobia.
  • 3) Pregnant or lactating woman.
  • 4) Other cases attending physician it is determined unsuitable for registration of the study.

研究者

发起方
meda Yukihiro

相似试验